Fibroblast growth factor 20 attenuates pathological cardiac hypertrophy by activating the SIRT1 signaling pathway

Chen, Yunjie; Zhou, Xuan; Mei, Lin; Sui, Yanru; Chen, Gen; Chen, Huinan; He, Shengqu; Jin, Cheng; Hu, Zhicheng; Li, Wanqian; Wang, Yan; Lin, Zhu; Chen, Peng; Jin, Litai; Guan, Xueqiang; Wang, Xu

doi:10.1038/s41419-022-04724-w

Cited by 11 publications

(8 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, fibroblast growth factor 20 reduces pathological cardiac hypertrophy by activating the signaling pathway of the deacetylase SIRT1, inducing deacetylation of FOXO1 and reducing oxidative stress. 237 In addition to senescent cardiomyocytes, senescent nonmyocytes in the heart, such as endothelial cells, can also be observed in HF. 238 Myocardial hypertrophy and interstitial fibrosis have been found to occur in aging-accelerated mice at 24 weeks of age.…”

Section: Pathogenic and Regulatory Mechanisms Of Aging-related Diseasesmentioning

confidence: 99%

Aging and aging-related diseases: from molecular mechanisms to interventions and treatments

Guo

Huang

Dou

et al. 2022

Sig Transduct Target Ther

467

160

View full text Add to dashboard Cite

Aging is a gradual and irreversible pathophysiological process. It presents with declines in tissue and cell functions and significant increases in the risks of various aging-related diseases, including neurodegenerative diseases, cardiovascular diseases, metabolic diseases, musculoskeletal diseases, and immune system diseases. Although the development of modern medicine has promoted human health and greatly extended life expectancy, with the aging of society, a variety of chronic diseases have gradually become the most important causes of disability and death in elderly individuals. Current research on aging focuses on elucidating how various endogenous and exogenous stresses (such as genomic instability, telomere dysfunction, epigenetic alterations, loss of proteostasis, compromise of autophagy, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, deregulated nutrient sensing) participate in the regulation of aging. Furthermore, thorough research on the pathogenesis of aging to identify interventions that promote health and longevity (such as caloric restriction, microbiota transplantation, and nutritional intervention) and clinical treatment methods for aging-related diseases (depletion of senescent cells, stem cell therapy, antioxidative and anti-inflammatory treatments, and hormone replacement therapy) could decrease the incidence and development of aging-related diseases and in turn promote healthy aging and longevity.

show abstract

Section: Pathogenic and Regulatory Mechanisms Of Aging-related Diseasesmentioning

confidence: 99%

Aging and aging-related diseases: from molecular mechanisms to interventions and treatments

Guo

Huang

Dou

et al. 2022

Sig Transduct Target Ther

467

160

View full text Add to dashboard Cite

show abstract

“…It has anti-hypertrophic effect which is greatly counteracted in SIRT1 knockout mice. Furthermore, these mice also presented an increase in oxidative stress (Chen et al, 2022b).…”

Section: Regulation Of Foxo1 Transcription Factorsmentioning

confidence: 87%

Activation of the sirtuin silent information regulator 1 pathway inhibits pathological myocardial remodeling

Wang

Zhao²,

Wu³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Myocardial remodeling refers to structural and functional disorders of the heart caused by molecular biological changes in the cardiac myocytes in response to neurological and humoral factors. A variety of heart diseases, such as hypertension, coronary artery disease, arrhythmia, and valvular heart disease, can cause myocardial remodeling and eventually lead to heart failure. Therefore, counteracting myocardial remodeling is essential for the prevention and treatment of heart failure. Sirt1 is a nicotinamide adenine dinucleotide+-dependent deacetylase that plays a wide range of roles in transcriptional regulation, energy metabolism regulation, cell survival, DNA repair, inflammation, and circadian regulation. It positively or negatively regulates myocardial remodeling by participating in oxidative stress, apoptosis, autophagy, inflammation, and other processes. Taking into account the close relationship between myocardial remodeling and heart failure and the involvement of SIRT1 in the development of the former, the role of SIRT1 in the prevention of heart failure via inhibition of myocardial remodeling has received considerable attention. Recently, multiple studies have been conducted to provide a better understanding of how SIRT1 regulates these phenomena. This review presents the progress of research involving SIRT1 pathway involvement in the pathophysiological mechanisms of myocardial remodeling and heart failure.

show abstract

“…FGF-20 has favorable roles in several chronic diseases. For example, FGF-20 plays a protective role in cardiac hypertrophy by activating silent information regulator 1 to inhibit oxidative stress-induced myocardial injury[ 78 ]. Increased plasma FGF-20 protein can delay the progression of diabetic renal diseases at the end stage[ 79 ].…”

Section: Fgfs Play An Important Role In Diabetes and Related Diseasesmentioning

confidence: 99%

Roles of fibroblast growth factors in the treatment of diabetes

Zhang,

Yang

2024

World J Diabetes

View full text Add to dashboard Cite

Diabetes affects about 422 million people worldwide, causing 1.5 million deaths each year. However, the incidence of diabetes is increasing, including several types of diabetes. Type 1 diabetes (5%-10% of diabetic cases) and type 2 diabetes (90%-95% of diabetic cases) are the main types of diabetes in the clinic. Accumulating evidence shows that the fibroblast growth factor (FGF) family plays important roles in many metabolic disorders, including type 1 and type 2 diabetes. FGF consists of 23 family members (FGF-1-23) in humans. Here, we review current findings of FGFs in the treatment of diabetes and management of diabetic complications. Some FGFs (e.g., FGF-15, FGF-19, and FGF-21) have been broadly investigated in preclinical studies for the diagnosis and treatment of diabetes, and their therapeutic roles in diabetes are currently under investigation in clinical trials. Overall, the roles of FGFs in diabetes and diabetic complications are involved in numerous processes. First, FGF intervention can prevent high-fat diet-induced obesity and insulin resistance and reduce the levels of fasting blood glucose and triglycerides by regulating lipolysis in adipose tissues and hepatic glucose production. Second, modulation of FGF expression can inhibit renal and cardiac fibrosis by regulating the expression of extracellular matrix components, promote diabetic wound healing process and bone repair, and inhibit cancer cell proliferation and migration. Finally, FGFs can regulate the activation of glucose-excited neurons and the expression of thermogenic genes.

show abstract

Fibroblast growth factor 20 attenuates pathological cardiac hypertrophy by activating the SIRT1 signaling pathway

Cited by 11 publications

References 59 publications

Aging and aging-related diseases: from molecular mechanisms to interventions and treatments

Aging and aging-related diseases: from molecular mechanisms to interventions and treatments

Activation of the sirtuin silent information regulator 1 pathway inhibits pathological myocardial remodeling

Roles of fibroblast growth factors in the treatment of diabetes

Contact Info

Product

Resources

About